Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real‐World Multicenter Study

Documenti analoghi

• Editorial Comment to “Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real‐World Multicenter Study”
  di: Nozomi Hayakawa, et al.
  Pubblicazione: (2025)
• Editorial Comment to “Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First‐Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real‐World Study ( YUSHIMA Study)”
  di: Nozomi Hayakawa, et al.
  Pubblicazione: (2026)
• Editorial Comment to “Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma”
  di: Nozomi Hayakawa, et al.
  Pubblicazione: (2025)
• Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
  di: Masanao Shinohara, et al.
  Pubblicazione: (2026)
• Editorial Comment to “Efficacy and safety of dose‐dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle‐invasive bladder cancer”
  di: Eiji Kikuchi, et al.
  Pubblicazione: (2024)